公开(公告)号：US20150183862A1

公开(公告)日：2015-07-02

申请号：US14582631

申请日：2014-12-24

Applicant: Vanderbilt University ,  Vanderbilt University

Inventor： James R. EDWARDS ,  Gregory R. MUNDY

IPC: C07K16/24

CPC classification number: C07K16/24 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/22 ,  C07K2317/76

Abstract: The invention regards the modulation of TGF-β activity by administering to a subject an antibody that binds to TGF-β, thereby increasing bone growth, bone formation, bone mass and bone strength. The antibody acts to increase osteoblast number and function while at the same time decreasing osteoclast number and function. Such drugs are useful in the treatment of diseases or disorders such as osteoporosis, Paget's disease, metastatic bone cancer, myeloma bone disease, bone fractures, etc.

Abstract translation: 本发明涉及TGF- 通过向受试者施用结合TGF-β1b的抗体，从而增加骨生长，骨形成，骨量和骨强度的活性。 抗体的作用是增加成骨细胞数量和功能，同时降低破骨细胞数量和功能。 这些药物可用于治疗诸如骨质疏松症，佩吉特氏病，转移性骨癌，骨髓瘤骨病，骨折等疾病或病症。